| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Smoking Cessation | 102 | 2023 | 1034 | 17.840 |
Why?
|
| Smoking | 77 | 2023 | 1452 | 9.950 |
Why?
|
| Smokers | 25 | 2022 | 200 | 6.990 |
Why?
|
| Tobacco Use Disorder | 31 | 2023 | 432 | 6.870 |
Why?
|
| Motivation | 30 | 2022 | 561 | 5.370 |
Why?
|
| Smoking Prevention | 26 | 2018 | 259 | 4.710 |
Why?
|
| Nicotine | 26 | 2022 | 350 | 4.110 |
Why?
|
| Tobacco Products | 23 | 2022 | 234 | 3.770 |
Why?
|
| Electronic Nicotine Delivery Systems | 11 | 2022 | 180 | 3.710 |
Why?
|
| Cigarette Smoking | 11 | 2022 | 104 | 3.010 |
Why?
|
| Mobile Applications | 5 | 2019 | 138 | 2.290 |
Why?
|
| Tobacco Use | 5 | 2020 | 98 | 2.220 |
Why?
|
| Tobacco, Smokeless | 5 | 2017 | 40 | 2.120 |
Why?
|
| Adult | 97 | 2023 | 21403 | 2.120 |
Why?
|
| Nicotinic Agonists | 14 | 2022 | 111 | 2.060 |
Why?
|
| Vaping | 7 | 2022 | 124 | 2.060 |
Why?
|
| Primary Health Care | 8 | 2022 | 703 | 2.020 |
Why?
|
| Humans | 157 | 2023 | 68618 | 1.880 |
Why?
|
| Female | 115 | 2022 | 38074 | 1.870 |
Why?
|
| Cues | 15 | 2020 | 654 | 1.850 |
Why?
|
| Tobacco | 5 | 2023 | 161 | 1.820 |
Why?
|
| Behavior Therapy | 9 | 2022 | 297 | 1.780 |
Why?
|
| Male | 105 | 2022 | 37321 | 1.760 |
Why?
|
| Counseling | 8 | 2019 | 280 | 1.690 |
Why?
|
| Health Behavior | 11 | 2019 | 458 | 1.640 |
Why?
|
| Telemedicine | 5 | 2022 | 700 | 1.570 |
Why?
|
| Behavior, Addictive | 9 | 2020 | 317 | 1.440 |
Why?
|
| Self Efficacy | 9 | 2022 | 199 | 1.400 |
Why?
|
| Varenicline | 10 | 2021 | 98 | 1.400 |
Why?
|
| Pilot Projects | 20 | 2022 | 1342 | 1.400 |
Why?
|
| Middle Aged | 61 | 2022 | 21147 | 1.340 |
Why?
|
| Surveys and Questionnaires | 19 | 2019 | 2800 | 1.270 |
Why?
|
| Young Adult | 44 | 2023 | 5717 | 1.180 |
Why?
|
| Craving | 8 | 2020 | 200 | 1.160 |
Why?
|
| Telephone | 6 | 2014 | 160 | 1.150 |
Why?
|
| Adolescent | 49 | 2023 | 8912 | 1.150 |
Why?
|
| Substance Withdrawal Syndrome | 11 | 2018 | 435 | 1.140 |
Why?
|
| Adaptation, Psychological | 3 | 2018 | 447 | 1.140 |
Why?
|
| Hotlines | 3 | 2014 | 51 | 1.100 |
Why?
|
| Depressive Disorder | 2 | 2019 | 621 | 0.980 |
Why?
|
| Stress, Psychological | 8 | 2020 | 824 | 0.950 |
Why?
|
| Intention | 6 | 2021 | 80 | 0.910 |
Why?
|
| Attitude to Health | 5 | 2012 | 403 | 0.910 |
Why?
|
| Bupropion | 6 | 2022 | 63 | 0.890 |
Why?
|
| Impulsive Behavior | 2 | 2015 | 85 | 0.860 |
Why?
|
| Menstrual Cycle | 5 | 2022 | 64 | 0.830 |
Why?
|
| Depression | 3 | 2018 | 943 | 0.820 |
Why?
|
| Social Environment | 4 | 2020 | 182 | 0.800 |
Why?
|
| Medication Adherence | 5 | 2021 | 335 | 0.790 |
Why?
|
| Tobacco Use Cessation | 3 | 2023 | 44 | 0.750 |
Why?
|
| Propylene Glycol | 1 | 2020 | 5 | 0.720 |
Why?
|
| Glycerol | 1 | 2020 | 26 | 0.710 |
Why?
|
| Alcoholism | 5 | 2022 | 1109 | 0.690 |
Why?
|
| Vegetables | 1 | 2020 | 76 | 0.690 |
Why?
|
| Ambulatory Care | 2 | 2020 | 340 | 0.680 |
Why?
|
| Cross-Sectional Studies | 13 | 2018 | 2279 | 0.680 |
Why?
|
| Economics, Behavioral | 1 | 2019 | 12 | 0.670 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2019 | 782 | 0.670 |
Why?
|
| Health Policy | 3 | 2018 | 221 | 0.660 |
Why?
|
| Public Policy | 2 | 2017 | 71 | 0.650 |
Why?
|
| Communication Barriers | 1 | 2019 | 48 | 0.640 |
Why?
|
| Marijuana Abuse | 6 | 2012 | 251 | 0.640 |
Why?
|
| Prisoners | 2 | 2016 | 50 | 0.640 |
Why?
|
| Health Status Disparities | 3 | 2017 | 326 | 0.630 |
Why?
|
| United States | 18 | 2021 | 7367 | 0.630 |
Why?
|
| Language | 1 | 2019 | 120 | 0.610 |
Why?
|
| Psychotherapy | 3 | 2017 | 253 | 0.590 |
Why?
|
| South Carolina | 13 | 2020 | 2752 | 0.590 |
Why?
|
| Fatigue | 2 | 2020 | 132 | 0.580 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 848 | 0.570 |
Why?
|
| Perception | 1 | 2017 | 189 | 0.550 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 438 | 0.520 |
Why?
|
| Databases, Factual | 1 | 2018 | 622 | 0.520 |
Why?
|
| Research Design | 3 | 2020 | 729 | 0.510 |
Why?
|
| Treatment Outcome | 20 | 2019 | 7029 | 0.500 |
Why?
|
| Double-Blind Method | 10 | 2020 | 1738 | 0.500 |
Why?
|
| Dopamine Uptake Inhibitors | 3 | 2012 | 152 | 0.500 |
Why?
|
| Referral and Consultation | 2 | 2014 | 383 | 0.490 |
Why?
|
| Follow-Up Studies | 10 | 2019 | 3259 | 0.490 |
Why?
|
| Progesterone | 3 | 2022 | 115 | 0.480 |
Why?
|
| Lung Neoplasms | 4 | 2018 | 1173 | 0.480 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2019 | 468 | 0.470 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 378 | 0.450 |
Why?
|
| Risk-Taking | 2 | 2012 | 210 | 0.440 |
Why?
|
| Adolescent Behavior | 3 | 2012 | 264 | 0.440 |
Why?
|
| Longitudinal Studies | 6 | 2022 | 1054 | 0.440 |
Why?
|
| Tobacco Smoking | 4 | 2020 | 41 | 0.430 |
Why?
|
| Research Subjects | 1 | 2013 | 45 | 0.420 |
Why?
|
| Harm Reduction | 4 | 2020 | 21 | 0.420 |
Why?
|
| Prevalence | 6 | 2020 | 1619 | 0.420 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 3 | 2008 | 37 | 0.410 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 3 | 2010 | 189 | 0.410 |
Why?
|
| Personality | 1 | 2012 | 66 | 0.410 |
Why?
|
| Translations | 1 | 2012 | 12 | 0.410 |
Why?
|
| Head and Neck Neoplasms | 4 | 2022 | 561 | 0.400 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2012 | 52 | 0.400 |
Why?
|
| Ganglionic Stimulants | 3 | 2009 | 15 | 0.400 |
Why?
|
| Recurrence | 6 | 2019 | 948 | 0.400 |
Why?
|
| Ovary | 1 | 2012 | 99 | 0.390 |
Why?
|
| Spinal Cord Injuries | 2 | 2015 | 551 | 0.390 |
Why?
|
| Genetic Testing | 3 | 2008 | 159 | 0.390 |
Why?
|
| Quinoxalines | 5 | 2015 | 78 | 0.390 |
Why?
|
| Commerce | 3 | 2020 | 80 | 0.390 |
Why?
|
| Prospective Studies | 10 | 2020 | 3705 | 0.380 |
Why?
|
| Benzazepines | 5 | 2015 | 104 | 0.380 |
Why?
|
| Disclosure | 1 | 2011 | 45 | 0.380 |
Why?
|
| Logistic Models | 6 | 2015 | 1420 | 0.370 |
Why?
|
| Alcohol Drinking | 4 | 2020 | 805 | 0.350 |
Why?
|
| Taxes | 4 | 2020 | 31 | 0.350 |
Why?
|
| HIV Infections | 2 | 2019 | 791 | 0.350 |
Why?
|
| Time Factors | 7 | 2018 | 4655 | 0.340 |
Why?
|
| Substance-Related Disorders | 5 | 2019 | 1242 | 0.320 |
Why?
|
| Women's Health | 2 | 2015 | 148 | 0.320 |
Why?
|
| Marijuana Smoking | 2 | 2020 | 108 | 0.310 |
Why?
|
| Affect | 3 | 2015 | 218 | 0.310 |
Why?
|
| Sex Factors | 7 | 2020 | 1266 | 0.310 |
Why?
|
| Cross-Over Studies | 2 | 2020 | 260 | 0.300 |
Why?
|
| Acetylcysteine | 4 | 2021 | 296 | 0.290 |
Why?
|
| Estradiol | 2 | 2020 | 176 | 0.280 |
Why?
|
| Risk Reduction Behavior | 2 | 2012 | 174 | 0.280 |
Why?
|
| Luteal Phase | 4 | 2022 | 25 | 0.270 |
Why?
|
| Health Surveys | 3 | 2017 | 489 | 0.270 |
Why?
|
| Aged | 15 | 2018 | 14862 | 0.270 |
Why?
|
| Weight Gain | 1 | 2007 | 135 | 0.270 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2019 | 931 | 0.260 |
Why?
|
| Gender Identity | 2 | 2015 | 47 | 0.250 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2010 | 767 | 0.250 |
Why?
|
| Product Labeling | 3 | 2013 | 43 | 0.240 |
Why?
|
| Reproducibility of Results | 5 | 2019 | 2077 | 0.240 |
Why?
|
| Internet | 3 | 2015 | 390 | 0.240 |
Why?
|
| Feasibility Studies | 6 | 2022 | 652 | 0.240 |
Why?
|
| Administration, Intranasal | 4 | 2020 | 88 | 0.230 |
Why?
|
| Attitude | 2 | 2021 | 121 | 0.220 |
Why?
|
| Follicular Phase | 3 | 2014 | 15 | 0.220 |
Why?
|
| Decision Making | 1 | 2006 | 410 | 0.220 |
Why?
|
| Saliva | 2 | 2022 | 142 | 0.220 |
Why?
|
| Self Disclosure | 2 | 2015 | 55 | 0.220 |
Why?
|
| Galvanic Skin Response | 4 | 2010 | 67 | 0.210 |
Why?
|
| Data Collection | 3 | 2020 | 420 | 0.210 |
Why?
|
| Cannabis | 2 | 2023 | 115 | 0.210 |
Why?
|
| Receptors, Nicotinic | 1 | 2022 | 41 | 0.210 |
Why?
|
| United Kingdom | 3 | 2017 | 152 | 0.210 |
Why?
|
| Canada | 3 | 2017 | 267 | 0.200 |
Why?
|
| Australia | 3 | 2017 | 235 | 0.200 |
Why?
|
| Ischemic Attack, Transient | 1 | 2023 | 167 | 0.200 |
Why?
|
| False Negative Reactions | 2 | 2019 | 63 | 0.190 |
Why?
|
| Oxytocin | 2 | 2020 | 124 | 0.190 |
Why?
|
| Ecological Momentary Assessment | 2 | 2018 | 16 | 0.190 |
Why?
|
| Prisons | 1 | 2001 | 18 | 0.190 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 148 | 0.190 |
Why?
|
| Analysis of Variance | 2 | 2013 | 1040 | 0.190 |
Why?
|
| Social Control, Formal | 1 | 2020 | 12 | 0.190 |
Why?
|
| Administration, Oral | 3 | 2014 | 411 | 0.180 |
Why?
|
| England | 1 | 2020 | 64 | 0.180 |
Why?
|
| Heart Rate | 4 | 2010 | 568 | 0.180 |
Why?
|
| Neoplasms | 3 | 2021 | 1667 | 0.180 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2020 | 71 | 0.170 |
Why?
|
| Consumer Behavior | 1 | 2020 | 68 | 0.170 |
Why?
|
| Cost-Benefit Analysis | 1 | 2022 | 504 | 0.170 |
Why?
|
| Employment | 1 | 2001 | 154 | 0.170 |
Why?
|
| Smoking Devices | 1 | 2019 | 6 | 0.170 |
Why?
|
| Solvents | 1 | 2020 | 109 | 0.170 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 207 | 0.170 |
Why?
|
| Netherlands | 1 | 2019 | 68 | 0.170 |
Why?
|
| Patient Health Questionnaire | 1 | 2019 | 9 | 0.170 |
Why?
|
| Spain | 1 | 2019 | 34 | 0.170 |
Why?
|
| Social Support | 2 | 2013 | 423 | 0.160 |
Why?
|
| Social Class | 2 | 2017 | 127 | 0.160 |
Why?
|
| Stress, Physiological | 1 | 2020 | 215 | 0.160 |
Why?
|
| Heroin Dependence | 1 | 1998 | 23 | 0.160 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1998 | 30 | 0.160 |
Why?
|
| Tornadoes | 2 | 2015 | 54 | 0.160 |
Why?
|
| Cotinine | 3 | 2015 | 40 | 0.150 |
Why?
|
| Sex Distribution | 2 | 2016 | 274 | 0.150 |
Why?
|
| Health Services Research | 1 | 2019 | 209 | 0.150 |
Why?
|
| Sex Characteristics | 1 | 2019 | 295 | 0.150 |
Why?
|
| Self-Control | 1 | 2017 | 9 | 0.150 |
Why?
|
| Forecasting | 1 | 2018 | 277 | 0.150 |
Why?
|
| Retrospective Studies | 3 | 2020 | 7277 | 0.140 |
Why?
|
| Alabama | 2 | 2015 | 98 | 0.140 |
Why?
|
| Cross-Cultural Comparison | 1 | 2016 | 68 | 0.140 |
Why?
|
| Urologic Surgical Procedures | 1 | 2016 | 47 | 0.140 |
Why?
|
| Incidence | 5 | 2019 | 1603 | 0.130 |
Why?
|
| Age Factors | 4 | 2013 | 1864 | 0.130 |
Why?
|
| Robotic Surgical Procedures | 1 | 2016 | 49 | 0.130 |
Why?
|
| Disaster Victims | 1 | 2015 | 13 | 0.130 |
Why?
|
| Fellowships and Scholarships | 1 | 2016 | 127 | 0.130 |
Why?
|
| Community Health Planning | 1 | 2015 | 19 | 0.130 |
Why?
|
| Quality of Life | 2 | 2022 | 1515 | 0.130 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 1851 | 0.130 |
Why?
|
| Self Report | 4 | 2019 | 371 | 0.130 |
Why?
|
| Learning | 1 | 2017 | 186 | 0.120 |
Why?
|
| Socioeconomic Factors | 6 | 2015 | 955 | 0.120 |
Why?
|
| Demography | 2 | 2016 | 279 | 0.120 |
Why?
|
| Laparoscopy | 1 | 2016 | 237 | 0.120 |
Why?
|
| Cohort Studies | 3 | 2015 | 2358 | 0.120 |
Why?
|
| Focus Groups | 2 | 2011 | 247 | 0.110 |
Why?
|
| Tobacco Smoke Pollution | 2 | 2012 | 127 | 0.110 |
Why?
|
| Patient Selection | 2 | 2019 | 592 | 0.110 |
Why?
|
| Lung | 1 | 2018 | 849 | 0.110 |
Why?
|
| Intention to Treat Analysis | 1 | 2013 | 38 | 0.110 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 2 | 2010 | 151 | 0.110 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2013 | 35 | 0.110 |
Why?
|
| Health Resources | 1 | 2013 | 76 | 0.100 |
Why?
|
| Genotype | 2 | 2022 | 786 | 0.100 |
Why?
|
| Health Services | 1 | 2013 | 87 | 0.100 |
Why?
|
| Administration, Cutaneous | 3 | 2013 | 56 | 0.100 |
Why?
|
| Models, Psychological | 1 | 2013 | 180 | 0.100 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2012 | 128 | 0.100 |
Why?
|
| Electronics | 2 | 2022 | 25 | 0.100 |
Why?
|
| Hospitalization | 1 | 2017 | 978 | 0.100 |
Why?
|
| Clinical Competence | 1 | 2016 | 657 | 0.100 |
Why?
|
| Automobiles | 1 | 2011 | 26 | 0.100 |
Why?
|
| Housing | 1 | 2011 | 38 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 629 | 0.090 |
Why?
|
| Factor Analysis, Statistical | 1 | 2011 | 201 | 0.090 |
Why?
|
| Confidence Intervals | 1 | 2011 | 242 | 0.090 |
Why?
|
| Propylamines | 1 | 2010 | 22 | 0.090 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2010 | 20 | 0.090 |
Why?
|
| Attention | 1 | 2012 | 225 | 0.090 |
Why?
|
| Regression Analysis | 1 | 2012 | 737 | 0.090 |
Why?
|
| Survivors | 1 | 2013 | 256 | 0.090 |
Why?
|
| Risk Factors | 6 | 2023 | 5731 | 0.090 |
Why?
|
| Stroke | 1 | 2023 | 2163 | 0.090 |
Why?
|
| Research | 2 | 2022 | 214 | 0.090 |
Why?
|
| Interviews as Topic | 1 | 2011 | 392 | 0.090 |
Why?
|
| Comorbidity | 2 | 2008 | 1426 | 0.090 |
Why?
|
| Disasters | 2 | 2015 | 204 | 0.080 |
Why?
|
| Buspirone | 1 | 2009 | 36 | 0.080 |
Why?
|
| Students | 1 | 2011 | 233 | 0.080 |
Why?
|
| Public Health | 2 | 2021 | 201 | 0.080 |
Why?
|
| Anti-Anxiety Agents | 1 | 2009 | 107 | 0.080 |
Why?
|
| Conditioning, Operant | 1 | 2010 | 241 | 0.080 |
Why?
|
| Cluster Analysis | 1 | 2009 | 219 | 0.080 |
Why?
|
| Self Medication | 1 | 2008 | 25 | 0.080 |
Why?
|
| Restaurants | 1 | 2008 | 29 | 0.080 |
Why?
|
| Air Pollution, Indoor | 1 | 2008 | 26 | 0.080 |
Why?
|
| Particulate Matter | 1 | 2008 | 41 | 0.080 |
Why?
|
| Child | 4 | 2011 | 6405 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2015 | 1615 | 0.070 |
Why?
|
| Mass Screening | 1 | 2013 | 843 | 0.070 |
Why?
|
| Genetic Carrier Screening | 1 | 2007 | 25 | 0.070 |
Why?
|
| Bronchial Neoplasms | 1 | 2006 | 12 | 0.070 |
Why?
|
| Policy | 2 | 2020 | 58 | 0.070 |
Why?
|
| Psychometrics | 1 | 2009 | 514 | 0.070 |
Why?
|
| Preventive Medicine | 1 | 2006 | 48 | 0.070 |
Why?
|
| Pulmonary Emphysema | 1 | 2007 | 71 | 0.070 |
Why?
|
| Patient Compliance | 2 | 2019 | 402 | 0.070 |
Why?
|
| Self-Help Groups | 1 | 2006 | 38 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 1745 | 0.070 |
Why?
|
| Cannabinoids | 3 | 2012 | 90 | 0.060 |
Why?
|
| Community Networks | 1 | 2006 | 96 | 0.060 |
Why?
|
| Qualitative Research | 2 | 2020 | 369 | 0.060 |
Why?
|
| Coronary Disease | 1 | 2006 | 358 | 0.060 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2015 | 1506 | 0.060 |
Why?
|
| Carbon Monoxide | 2 | 2018 | 58 | 0.060 |
Why?
|
| Chewing Gum | 1 | 2004 | 6 | 0.060 |
Why?
|
| Tablets | 1 | 2022 | 19 | 0.050 |
Why?
|
| Arousal | 2 | 2014 | 168 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2A6 | 1 | 2022 | 5 | 0.050 |
Why?
|
| Southeastern United States | 2 | 2013 | 281 | 0.050 |
Why?
|
| Health Services Accessibility | 1 | 2006 | 581 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2022 | 220 | 0.050 |
Why?
|
| Age Distribution | 2 | 2014 | 320 | 0.050 |
Why?
|
| Vermont | 1 | 2001 | 21 | 0.050 |
Why?
|
| Preoperative Period | 1 | 2021 | 50 | 0.050 |
Why?
|
| Predictive Value of Tests | 3 | 2010 | 1465 | 0.050 |
Why?
|
| Neuroendocrine Cells | 1 | 2020 | 8 | 0.050 |
Why?
|
| Neurosecretory Systems | 1 | 2020 | 21 | 0.050 |
Why?
|
| Mental Disorders | 1 | 2006 | 659 | 0.050 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2020 | 150 | 0.040 |
Why?
|
| Pituitary-Adrenal System | 1 | 2020 | 138 | 0.040 |
Why?
|
| Survival Rate | 2 | 2013 | 1056 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2022 | 627 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2012 | 880 | 0.040 |
Why?
|
| Emotions | 1 | 2020 | 244 | 0.040 |
Why?
|
| Drug Substitution | 1 | 2018 | 19 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2019 | 123 | 0.040 |
Why?
|
| Hydrocortisone | 1 | 2020 | 291 | 0.040 |
Why?
|
| Substance Abuse Detection | 1 | 1998 | 66 | 0.040 |
Why?
|
| Personal Satisfaction | 1 | 2019 | 123 | 0.040 |
Why?
|
| Breath Tests | 1 | 2018 | 23 | 0.040 |
Why?
|
| Heroin | 1 | 1998 | 49 | 0.040 |
Why?
|
| Smartphone | 1 | 2018 | 69 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 191 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2020 | 374 | 0.040 |
Why?
|
| Mental Recall | 1 | 2017 | 72 | 0.030 |
Why?
|
| Animals | 2 | 2013 | 20881 | 0.030 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2016 | 85 | 0.030 |
Why?
|
| Missouri | 1 | 2015 | 44 | 0.030 |
Why?
|
| Hypertension | 2 | 2009 | 1535 | 0.030 |
Why?
|
| Transdermal Patch | 1 | 2015 | 21 | 0.030 |
Why?
|
| Extinction, Psychological | 1 | 2017 | 240 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2016 | 254 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 214 | 0.030 |
Why?
|
| Drug Approval | 1 | 2014 | 50 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 800 | 0.030 |
Why?
|
| Nitrosamines | 1 | 2013 | 18 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 4848 | 0.030 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2013 | 73 | 0.030 |
Why?
|
| Family | 1 | 2015 | 293 | 0.030 |
Why?
|
| Cocaine-Related Disorders | 1 | 1998 | 504 | 0.030 |
Why?
|
| Algorithms | 1 | 2019 | 1196 | 0.030 |
Why?
|
| Exercise | 1 | 1999 | 658 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 567 | 0.030 |
Why?
|
| Pediatrics | 1 | 2016 | 341 | 0.030 |
Why?
|
| Mexico | 1 | 2012 | 38 | 0.030 |
Why?
|
| Injury Severity Score | 1 | 2013 | 204 | 0.030 |
Why?
|
| Product Packaging | 1 | 2012 | 17 | 0.030 |
Why?
|
| Mental Health | 1 | 2015 | 278 | 0.030 |
Why?
|
| Marital Status | 1 | 2012 | 65 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 546 | 0.030 |
Why?
|
| Health Literacy | 1 | 2012 | 63 | 0.030 |
Why?
|
| History, 19th Century | 1 | 2012 | 95 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2012 | 127 | 0.030 |
Why?
|
| Income | 1 | 2012 | 167 | 0.020 |
Why?
|
| Length of Stay | 1 | 2015 | 780 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2012 | 248 | 0.020 |
Why?
|
| Nausea | 1 | 2011 | 47 | 0.020 |
Why?
|
| Linear Models | 1 | 2012 | 521 | 0.020 |
Why?
|
| Atomoxetine Hydrochloride | 1 | 2010 | 14 | 0.020 |
Why?
|
| Self Concept | 1 | 2011 | 132 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2010 | 120 | 0.020 |
Why?
|
| Placebos | 1 | 2010 | 195 | 0.020 |
Why?
|
| Universities | 1 | 2011 | 191 | 0.020 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2011 | 91 | 0.020 |
Why?
|
| Pain | 1 | 2013 | 472 | 0.020 |
Why?
|
| Sample Size | 1 | 2009 | 79 | 0.020 |
Why?
|
| Drug-Seeking Behavior | 1 | 2010 | 213 | 0.020 |
Why?
|
| Patient Participation | 1 | 2008 | 146 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 792 | 0.020 |
Why?
|
| Neurotoxins | 1 | 1986 | 30 | 0.020 |
Why?
|
| Kainic Acid | 1 | 1986 | 44 | 0.020 |
Why?
|
| Anesthetics | 1 | 1986 | 30 | 0.020 |
Why?
|
| Anxiety | 1 | 2009 | 422 | 0.020 |
Why?
|
| Aspartic Acid | 1 | 1986 | 65 | 0.020 |
Why?
|
| Hypnotics and Sedatives | 1 | 1986 | 96 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2009 | 867 | 0.020 |
Why?
|
| Analgesics | 1 | 1986 | 118 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2006 | 206 | 0.010 |
Why?
|
| Mississippi | 1 | 1999 | 11 | 0.010 |
Why?
|
| Minnesota | 1 | 1999 | 27 | 0.010 |
Why?
|
| Maryland | 1 | 1999 | 77 | 0.010 |
Why?
|
| Arteriosclerosis | 1 | 1999 | 137 | 0.010 |
Why?
|
| North Carolina | 1 | 1999 | 224 | 0.010 |
Why?
|
| Population Surveillance | 1 | 1999 | 285 | 0.010 |
Why?
|
| N-Methylaspartate | 1 | 1986 | 59 | 0.000 |
Why?
|
| Chick Embryo | 1 | 1986 | 379 | 0.000 |
Why?
|
| Retina | 1 | 1986 | 252 | 0.000 |
Why?
|